The MPS indication is streets behind the clinical development of OA, which they want to advance to full maturity before a deal. Incongruent, much?
Ann: Primary and Secondary endpoints met in MPS I Trial, page-36
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $71.79M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.5¢ | $31.10K | 153.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 73997 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 24197 | 5 |
View Market Depth
| Last trade - 11.50am 02/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |